Does cortisol raise glucose and shift lipids toward high triglycerides and low HDL?

Clinical and metabolic evidence

• Elevated hepatic glucose output: Cortisol directly drives endogenous glucose production in the liver. Clinical infusion and tracer kinetics studies show that acute and chronic cortisol elevations significantly increase the rate of glucose appearance in systemic circulation, directly raising postabsorptive plasma glucose levels.
• Atherogenic dyslipidemia: Research from clinical cohorts, particularly in patient populations with Cushing's syndrome, confirms that sustained cortisol excess produces a highly atherogenic lipid profile. Clinical data show hypertriglyceridemia prevalences reaching up to 53% in these cohorts, which is accompanied by a distinct shift toward low high-density lipoprotein cholesterol (HDL-C) levels. Resolving hypercortisolism clinically reverses elevated triglyceride levels.

Mechanistic explanations

• Transcriptional upregulation of gluconeogenesis: At the cellular level, cortisol binds to the intracellular glucocorticoid receptor (GR) inside hepatocytes. This complex translocates to the nucleus to upregulate the transcription of two rate-limiting gluconeogenic enzymes: phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), which accelerates the conversion of substrates into free glucose for export.
• Adipose lipolysis and VLDL overproduction: Cortisol promotes lipolysis in adipose tissue, driving a massive flux of free fatty acids to the liver. This stimulates hepatic de novo lipogenesis and triglyceride synthesis, preventing apolipoprotein B degradation and accelerating the assembly and secretion of very-low-density lipoproteins (VLDL).
• CETP-mediated HDL clearance: The excess of triglyceride-rich VLDL in circulation activates cholesteryl ester transfer protein (CETP). CETP exchanges triglycerides from VLDL for cholesteryl esters within HDL particles. These triglyceride-enriched HDL particles are rapidly degraded and cleared by hepatic lipase, causing a substantial drop in circulating HDL-C levels.
• Synergistic insulin resistance: Cortisol simultaneously induces systemic and hepatic insulin resistance. This blunts insulin’s ability to suppress hepatic glucose output and stop VLDL assembly, further reinforcing both hyperglycemia and dyslipidemia.

Bottom line

• Cortisol raises blood glucose and drives a high-triglyceride, low-HDL lipid pattern by transcriptionally activating hepatic gluconeogenesis, promoting adipose lipolysis to fuel VLDL overproduction, and accelerating CETP-mediated HDL clearance.